1. Search Result
Search Result
Results for "

BMX

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

2

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-80002
    BMX-IN-1
    Maximum Cited Publications
    7 Publications Verification

    BMX kinase inhibitor

    Btk BMX Kinase Cancer
    BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys 496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
    BMX-IN-1
  • HY-101267
    CHMFL-BMX-078
    3 Publications Verification

    CHMFL-BMX 078

    BMX Kinase Cancer
    CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
    CHMFL-BMX-078
  • HY-130574

    BMX-010 chloride

    Reactive Oxygen Species (ROS) Cancer
    MnTE-2-PyP (BMX-010) chloride is a ROS scavenger and potent radioprotector. MnTE-2-PyP also is a manganese porphyrin, protects normal prostate tissue from radiation damage. MnTE-2-PyP can be used for the research of diabetic prostate cancer .
    MnTE-2-PyP chloride
  • HY-139481
    TL-895
    1 Publications Verification

    Btk BMX Kinase Interleukin Related TNF Receptor Neurological Disease Inflammation/Immunology Cancer
    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor. TL-895 is active against recombinant BTK (average IC50: 1.5 nM) and inhibits only three additional kinases BLK, BMX (IC50 = 1.6 nM) and TXK with IC50 within tenfold of BTK activity. TL-895 inhibits BTK auto-phosphorylation at the Y223 phosphorylation site (IC50: 1-10 nM). The TL-895 effectively inhibits the production of inflammatory factors such as IL-8, IL-1β, MCP-1 and TNF-α by monocytes or macrophages, and reduces the chemotactic migration of MF cells towards SDF-1. TL-895 is used be for studies of chronic lymphocytic leukemia (CLL), myelofibrosis (MF), and B-cell malignancies .
    TL-895
  • HY-125662A

    Reactive Oxygen Species (ROS) Apoptosis Metabolic Disease
    BMX-001, a novel redox-active metalloporphyrin, improves islet function and engraftment in a murine transplant model. BMX-001 reduces apoptosis in human and murine islets. BMX-001 significantly improves static-glucose stimulated insulin secretion (sGSIS) responses in murine islets. BMX-001 can significantly restore euglycemia in murine islet studies in the presence of the MnSOD. BMX-001 reduces the generation of ROS in a murine islet isolation and culture model .
    BMX-001
  • HY-111553

    EGFR Cancer
    TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMXHER4BLK、EGFR、JAK3SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2, HER3, and downstream effectors .
    TAS0728
  • HY-176498

    BMX

    VEGFR FAK Akt PERK Cancer
    NBM-T-BMX-OS01 is an Osthole (HY-N0054) derivative. NBM-T-BMX-OS01 inhibits the phosphorylation of VEGFR2, FAK, Akt and ERK. NBM-T-BMX-OS01 has anti-angiogenic activity. NBM-T-BMX-OS01 has anti-cancer activity against colorectal cancer .
    NBM-T-BMX-OS01
  • HY-174142

    BMX Kinase Cardiovascular Disease Inflammation/Immunology
    IHMT-15130 is a highly potent irreversible BMX kinase inhibitor (IC50=1.47 nM). IHMT-15130 inhibits the secretion of inflammatory cytokines, blocks inflammatory signaling pathways, and alleviates Angiotensin II-induced myocardial hypertrophy in mice. IHMT-15130 is promising for research of myocardial hypertrophy .
    IHMT-15130
  • HY-145373

    Btk Inflammation/Immunology
    BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases .
    BMS-986143
  • HY-173057

    BMX Kinase Apoptosis Autophagy Cancer
    BMX-IN-3 (B6a) is an irreversible and selective BMX inhibitor, with an IC50 of 12 nM. BMX-IN-3 (B6a) promots cell cycle arrest and apoptosis, triggers protective autophagy, and suppresses the BMX/AKT/mTOR pathway. BMX-IN-3 (B6a) can be used in the research for Gastric Carcinoma .
    BMX-IN-3
  • HY-117900

    Btk Inflammation/Immunology
    PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively .
    PF-06250112
  • HY-RS01558

    Small Interfering RNA (siRNA) Others

    Bmx Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmx gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bmx Mouse Pre-designed siRNA Set A
    Bmx Mouse Pre-designed siRNA Set A
  • HY-RS01559

    Small Interfering RNA (siRNA) Others

    Bmx Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmx gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bmx Rat Pre-designed siRNA Set A
    Bmx Rat Pre-designed siRNA Set A
  • HY-RS01557

    Small Interfering RNA (siRNA) Others

    BMX Human Pre-designed siRNA Set A contains three designed siRNAs for BMX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BMX Human Pre-designed siRNA Set A
    BMX Human Pre-designed siRNA Set A
  • HY-148585

    Btk Cancer
    BTK-IN-22 is a BTK inhibitor (IC50: 0.9 nM). BTK-IN-22 also inhibits BLX and BMX with IC50s of 1.4 and 1.2 nM respectively. BTK-IN-22 shows improved kinase selectivity compared to Ibrutinib (HY-10997)
    BTK-IN-22
  • HY-148594

    Btk Cancer
    BTK-IN-23 is a BTK inhibitor (IC50: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC50s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997) .
    BTK-IN-23
  • HY-117900A

    Btk Inflammation/Immunology
    (Rac)-PF-0625011 is a racemate of PF-06250112. PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor and shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC .
    (Rac)-PF-06250112
  • HY-173280

    CHNQD-01228

    Arf Family GTPase BMX Kinase Cancer
    Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins. The IC50 value for the proliferation of T24 cells is 0.22 μM. It can also dose-dependently inhibit the migration and colony formation of T24 cells, induce G1 phase arrest and trigger Apoptosis. Brefeldin A 4-O-nicotinate exerts its anti-cancer activity by targeting the BMX protein to inhibit the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, as well as by inhibiting the Arf1 protein to eliminate bladder cancer stem cells and activate anti-tumor immunity. Brefeldin A 4-O-nicotinate can be used in the research related to bladder cancer .
    Brefeldin A 4-O-nicotinate
  • HY-101267R

    CHMFL-BMX 078 (Standard)

    BMX Kinase Reference Standards Cancer
    CHMFL-BMX-078 (Standard) is the analytical standard of CHMFL-BMX-078 (HY-101267). This product is intended for research and analytical applications. CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
    CHMFL-BMX-078 (Standard)
  • HY-182902

    BMX Kinase Apoptosis Cancer
    IHMT-15137 is a BMX inhibitor with an IC50 of 26.97 nM. IHMT-15137 covalently binds to BMX Cys496 within the ATP-binding pocket, inhibits BMX phosphorylation at Tyr566, and disrupts the BMX-ERK1/2-Cyclin D1/CDK4/6-E2F1 signaling axis. IHMT-15137 reduces E2F1 protein stability via decreased Ser332/337 phosphorylation, increased ubiquitination, and ubiquitin-proteasome pathway degradation. IHMT-15137 induces cell cycle arrest, apoptosis, DNA damage, and suppresses cell migration and invasion. IHMT-15137 can be used for the research of small cell lung cancer .
    IHMT-15137
  • HY-182293

    Btk Src BMX Kinase FLT3 Pim Inflammation/Immunology Cancer
    BTK-IN-48 is a BTK inhibitor with an IC50 of 1.14 μM. BTK-IN-48 inhibits recombinant BTK and c-Src, and exerts moderate inhibitory effects on LCK, BMX/ETK, FLT3 and PIM1. BTK-IN-48 can be used in the research of B-cell malignancies and autoimmune diseases .
    BTK-IN-48
  • HY-183682

    EGFR p38 MAPK ERK Akt Cancer
    AZ14289671 is an orally active, blood-brain barrier-penetrant tyrosine kinase (tyrosine kinase) inhibitor (TKI) that specifically targets non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (EGFR Exon20Ins), while largely sparing wild-type EGFR to reduce off-target toxicities such as rash and diarrhea. AZ14289671 inhibits the downstream MAPK/ERK/AKT pathway, suppressing tumor cell proliferation, survival and migration. AZ14289671 can be used for NSCLC research .
    AZ14289671

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: